Skip to main content
padlock icon - secure page this page is secure

Targeting Vascular Endothelial Growth Factor in Neuroblastoma

Buy Article:

$68.00 + tax (Refund Policy)

Angiogenesis is critical to tumor growth and metastasis and is dependent on growth factors, such as vascular endothelial growth factor (VEGF). The most characterized angiogenic factor, VEGF is an endothelial cell mitogen and permeability factor that has been found to be overexpressed in almost all human cancers. In a number of tumor model systems, antagonism of the VEGF pathway results in inhibition of angiogenesis and tumor growth. Specifically, VEGF inhibition has been shown to suppress tumor growth, decrease microvasculature, and induce apoptosis of endothelial cells. This close relationship between hypoxia, angiogenesis, and tumor growth makes VEGF and VEGF receptors attractive targets for anti-neoplastic therapies. However, in neuroblastoma, a vascular, aggressive pediatric solid tumor, VEGF therapies has demonstrated limited success, which may be due to resistance. Identifying synergistic anti-angiogenic targets may improve efficacy of VEGF treatments in neurobasltoma. In this article, we review the state of VEGF-targeted therapies, the results of recent clinical trials, as well as the future of novel anti-VEGF therapeutics. We will follow this with a review of VEGF treatment in the aggressive, pediatric malignancy, neuroblastoma, and discuss combination therapy of VEGF treatments with chemotherapy and other molecular targeted drugs.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Vascular endothelial growth factor; angiogenesis; clinical trials; neuroblastoma

Document Type: Research Article

Publication date: July 1, 2013

More about this publication?
  • Current Angiogenesis publishes expert review, original research articles, drug clinical trial studies and special topics on angiogenesis, covering all aspects from preclinical to clinical research pertaining to both neoplastic and non-neoplastic disorders.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more